Biogen and Japanese partner Eisai have found an experimental drug, which shows slowing of declines in memory and thinking, clearly associated with Alzheimer’s disease in a clinical trial. This gives support to the thesis that when buildups of amyloid plaques in the brain are targeted it can alter the course of the disease.
It is obvious that along with technological advancements like telehealth solutions, telehealth software, patient engagement solutions, etc we are witnessing progress in combating various diseases.
Eisai reported today at the Alzheimer’s Association International Conference in Chicago that the drug is dubbed BAN2401 and it slows decline associated with Alzheimer’s disease by 30% at its highest dose in the trial as compared to placebo after 18 months.
This slowing in progression comes because the drug considerably reduces buildups of amyloid plaques in the brain, by 93% at the highest dose. 30% slowing of Alzheimer’s progression was measured by a scale known as Alzheimer’s Disease Composite Score or ADCOMS. This score is basically a combination of commonly used endpoints that gauges cognition or the ability to remember things and think clearly.